The Eyerising Myopia Management Device (EMMD) is a non-invasive, home-use technology designed to slow myopia progression through repeated low-level red-light (RLRL) therapy.
The treatment protocol consists of two three-minute sessions per day, five days per week. Supported by more than 40 peer-reviewed publications including randomised control trials and real-world studies,* EMMD has received regulatory approvals in Australia (ARTG ID: 412752), New Zealand, Europe, and other markets.
Clinical studies have reported significant reductions in axial elongation, with one study reporting axial shortening in 53.3% of participants with high myopia.1 Available through more than 100 clinics across Australia and New Zealand, EMMD provides eye care professionals with an additional evidence-based option for myopia management.
Contact: Eyerising International (AUS) 1800 039 374 or eyerisinginternational.com
*Studies available from Eyerising International on request.
Reference
- Xu Y, Cui L, Zou H, et al. Repeated low-level red-light therapy for myopia control in high myopia children and adolescents: a randomized clinical trial. Ophthalmology. 2024 Jun 5:S0161-6420(24)00318-X. doi: 10.1016/j.ophtha.2024.05.023.
